3 ms·

Same. At this point I think it would be more than reasonable to suspend all IP related to those treatments, until all demand is met.

• anovikov 3y ago
  It's not about the IP. They have plenty of resources - Novo Nordisk is the largest cap European company. It's just that scaling of production is hard. It's hard because it's meant to be hard. No need to look for scapegoats here. They are doing everything possible to produce as much as quickly as possible and IP certainly helps them do it sooner (because patents are not infinite duration), rather than harms. If anyone has resources to shore up production facilities, components, people etc. it's them because they can get the most out of it, so it's not like "if everyone tries to do it they will do it sooner".
  • derelicta 3y ago
    I remember reading how the patent applies to the pen and not the molecule. Apparently, the production of the hormone itself isnt incredibly tough, its mostly the pen thats problematic; it is meant to be really easy to apply and thus is hard to produce. But I dont understand why having more competitors trying to replicate your pen would be a bad idea. Those treatments are horribly expensive, so competition is more than welcome imo.